A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma-Reference-Cited by-同舟云学术

A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma

Published:2018-10-02 Issue:2 Volume:25 Page:478-486
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Laubach Jacob P.,Liu Chia-Jen,Raje Noopur S.,Yee Andrew J.,Armand Philippe,Schlossman Robert L.,Rosenblatt Jacalyn,Hedlund Jacquelyn,Martin Michael,Reynolds Craig,Shain Kenneth H.,Zackon Ira,Stampleman Laura,Henrick Patrick,Rivotto Bradley,Hornburg Kalvis T.V.,Dumke Henry J.,Chuma Stacey,Savell Alexandra,Handisides Damian R.,Kroll Stew,Anderson Kenneth C.,Richardson Paul G.,Ghobrial Irene M.

Funder

Leukemia and Lymphoma Society

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multi-omic analysis and validation reveal ZBP1 as a potential prognostic and immunotherapy-related biomarker in head and neck squamous cell carcinoma;Journal of Stomatology, Oral and Maxillofacial Surgery;2024-09

2. Advancements in microenvironment-based therapies: transforming the landscape of multiple myeloma treatment;Frontiers in Oncology;2024-07-17

3. Role played by MDSC in colitis-associated colorectal cancer and potential therapeutic strategies;Journal of Cancer Research and Clinical Oncology;2024-05-08

4. Probiotic Escherichia coli Nissle 1917 propelled micro-robot with pH sensitivity for hypoxia targeted intestinal tumor therapy;Colloids and Surfaces B: Biointerfaces;2023-05

5. Modified isotonic regression based phase I/II clinical trial design identifying optimal biological dose;Contemporary Clinical Trials;2023-04